SerineThreonine Protein Kinase PLK1 - Pipeline Review, H2 2019
SerineThreonine Protein Kinase PLK1 - Pipeline Review, H2 2019
SUMMARY
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report SerineThreonine Protein Kinase PLK1 - Pipeline Review, H2 2019, outlays comprehensive information on the Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Serine/threonine-protein kinase PLK1 is an enzyme encoded by the PLK1 (polo-like kinase 1) gene. It is highly expressed during mitosis and elevated levels are found in many different types of cancer. Depletion of this protein in cancer cells dramatically inhibited cell proliferation and induced apoptosis. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 2, 1, 1, 3 and 1 respectively.
Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Leukemia, Myelodysplastic Syndrome, Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer, Skin Cancer, Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anal Cancer, Breast Cancer, Cervical Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Glioma, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Human Papillomavirus (HPV) Associated Cancer, Juvenile Myelomonocytic Leukemia (JMML), Lung Cancer, Lymphoma, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Penile Cancer, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rhabdomyosarcoma, Sarcomas, Small-Cell Lung Cancer, Solid Tumor, Squamous Cell Carcinoma, Squamous Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer (TNBC).
Furthermore, this report also reviews key players involved in Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
SUMMARY
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report SerineThreonine Protein Kinase PLK1 - Pipeline Review, H2 2019, outlays comprehensive information on the Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Serine/threonine-protein kinase PLK1 is an enzyme encoded by the PLK1 (polo-like kinase 1) gene. It is highly expressed during mitosis and elevated levels are found in many different types of cancer. Depletion of this protein in cancer cells dramatically inhibited cell proliferation and induced apoptosis. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 2, 1, 1, 3 and 1 respectively.
Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Leukemia, Myelodysplastic Syndrome, Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer, Skin Cancer, Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anal Cancer, Breast Cancer, Cervical Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Glioma, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Human Papillomavirus (HPV) Associated Cancer, Juvenile Myelomonocytic Leukemia (JMML), Lung Cancer, Lymphoma, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Penile Cancer, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rhabdomyosarcoma, Sarcomas, Small-Cell Lung Cancer, Solid Tumor, Squamous Cell Carcinoma, Squamous Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer (TNBC).
Furthermore, this report also reviews key players involved in Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21)
- The report reviews Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics and enlists all their major and minor projects
- The report assesses Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Overview
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Companies Involved in Therapeutics Development
Cyclacel Pharmaceuticals Inc
Korea United Pharm Inc
Le Sun Pharmaceuticals Ltd
Oncoheroes Biosciences Inc
Onconova Therapeutics Inc
PhoreMost Ltd
Takeda Pharmaceutical Co Ltd
Trovagene Inc
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Drug Profiles
Antisense Oligonucleotide to Target MIR34 and PLK1 for Pancreatic Ductal Adenocarcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CYC-140 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LS-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onvansertib fumarate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PM-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rigosertib sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PLK1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PLK1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UN-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
volasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Dormant Products
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Discontinued Products
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Product Development Milestones
Featured News & Press Releases
Dec 17, 2019: Onconova Therapeutics and Pint Pharma announce Brazilian Health Authority approval for initiating INSPIRE trial with intravenous Rigosertib in higher-risk myelodysplastic syndromes in Brazil
Dec 10, 2019: Drug combination shows promise in preclinical models of triple negative breast cancer
Dec 09, 2019: Onconova Therapeutics announces data on genomic profiles of higher risk myelodysplastic syndromes patients refractory to azacitidine therapy enrolled into the pivotal INSPIRE trial and updated oral rigosertib data informing a potential adaptive clinical trial design at the American Society of Hematology 2019 Annual Meeting
Dec 09, 2019: Efficacy, durability of response and safety of Onvansertib demonstrated in completed phase 1b trial in AML patients presented in oral session at ASH
Dec 06, 2019: Inceptua Medicines Access and Onconova Therapeutics announce pre-approval access collaboration for Rigosertib in selected countries outside the US
Dec 04, 2019: Trovagene announces data showing ability of onvansertib to rescue venetoclax-resistance in acute myeloid leukemia (AML)
Nov 14, 2019: Trovagene presents positive data in metastatic prostate cancer phase 2 trial showing clinical response in patients resistant to Zytiga
Nov 07, 2019: Onconova announces five presentations on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2019 Annual Meeting & Exposition
Nov 06, 2019: Trovagene announces data from acute myeloid leukemia (AML) Phase 1b/2 trial of Onvansertib chosen for oral presentation at ASH 2019 Annual Meeting
Oct 24, 2019: Onconova affirms planned completion of pivotal phase 3 INSPIRE study of Rigosertib in Myelodysplastic Syndromes by 1H20 and provides research & development update
Oct 22, 2019: Trovagene announces positive response to treatment in phase 1b/2 trial of Onvansertib in patients with KRAS-mutated metastatic colorectal cancer
Oct 10, 2019: Mission Bio awarded grant to measure minimal residual disease related to cancer relapse with single cell genomics
Oct 02, 2019: Data presented at ESMO provides rationale for clinical trial of Onvansertib in subset of patients with highly-aggressive Triple Negative Breast Cancer (TNBC)
Oct 01, 2019: Trovagene Presents Overview of Phase 1b/2 Trial of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer (mCRC) at ESMO
Sep 30, 2019: Positive data from Trovagene phase 1b/2 study of onvansertib featured in oral presentation at European Society for Medical Oncology (ESMO) Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Overview
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Companies Involved in Therapeutics Development
Cyclacel Pharmaceuticals Inc
Korea United Pharm Inc
Le Sun Pharmaceuticals Ltd
Oncoheroes Biosciences Inc
Onconova Therapeutics Inc
PhoreMost Ltd
Takeda Pharmaceutical Co Ltd
Trovagene Inc
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Drug Profiles
Antisense Oligonucleotide to Target MIR34 and PLK1 for Pancreatic Ductal Adenocarcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CYC-140 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LS-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onvansertib fumarate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PM-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rigosertib sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PLK1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PLK1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UN-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
volasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Dormant Products
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Discontinued Products
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Product Development Milestones
Featured News & Press Releases
Dec 17, 2019: Onconova Therapeutics and Pint Pharma announce Brazilian Health Authority approval for initiating INSPIRE trial with intravenous Rigosertib in higher-risk myelodysplastic syndromes in Brazil
Dec 10, 2019: Drug combination shows promise in preclinical models of triple negative breast cancer
Dec 09, 2019: Onconova Therapeutics announces data on genomic profiles of higher risk myelodysplastic syndromes patients refractory to azacitidine therapy enrolled into the pivotal INSPIRE trial and updated oral rigosertib data informing a potential adaptive clinical trial design at the American Society of Hematology 2019 Annual Meeting
Dec 09, 2019: Efficacy, durability of response and safety of Onvansertib demonstrated in completed phase 1b trial in AML patients presented in oral session at ASH
Dec 06, 2019: Inceptua Medicines Access and Onconova Therapeutics announce pre-approval access collaboration for Rigosertib in selected countries outside the US
Dec 04, 2019: Trovagene announces data showing ability of onvansertib to rescue venetoclax-resistance in acute myeloid leukemia (AML)
Nov 14, 2019: Trovagene presents positive data in metastatic prostate cancer phase 2 trial showing clinical response in patients resistant to Zytiga
Nov 07, 2019: Onconova announces five presentations on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2019 Annual Meeting & Exposition
Nov 06, 2019: Trovagene announces data from acute myeloid leukemia (AML) Phase 1b/2 trial of Onvansertib chosen for oral presentation at ASH 2019 Annual Meeting
Oct 24, 2019: Onconova affirms planned completion of pivotal phase 3 INSPIRE study of Rigosertib in Myelodysplastic Syndromes by 1H20 and provides research & development update
Oct 22, 2019: Trovagene announces positive response to treatment in phase 1b/2 trial of Onvansertib in patients with KRAS-mutated metastatic colorectal cancer
Oct 10, 2019: Mission Bio awarded grant to measure minimal residual disease related to cancer relapse with single cell genomics
Oct 02, 2019: Data presented at ESMO provides rationale for clinical trial of Onvansertib in subset of patients with highly-aggressive Triple Negative Breast Cancer (TNBC)
Oct 01, 2019: Trovagene Presents Overview of Phase 1b/2 Trial of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer (mCRC) at ESMO
Sep 30, 2019: Positive data from Trovagene phase 1b/2 study of onvansertib featured in oral presentation at European Society for Medical Oncology (ESMO) Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Cyclacel Pharmaceuticals Inc, H2 2019
Pipeline by Korea United Pharm Inc, H2 2019
Pipeline by Le Sun Pharmaceuticals Ltd, H2 2019
Pipeline by Oncoheroes Biosciences Inc, H2 2019
Pipeline by Onconova Therapeutics Inc, H2 2019
Pipeline by PhoreMost Ltd, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Pipeline by Trovagene Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Dormant Products, H2 2019 (Contd..3), H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Cyclacel Pharmaceuticals Inc, H2 2019
Pipeline by Korea United Pharm Inc, H2 2019
Pipeline by Le Sun Pharmaceuticals Ltd, H2 2019
Pipeline by Oncoheroes Biosciences Inc, H2 2019
Pipeline by Onconova Therapeutics Inc, H2 2019
Pipeline by PhoreMost Ltd, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Pipeline by Trovagene Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Dormant Products, H2 2019 (Contd..3), H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Cyclacel Pharmaceuticals Inc
Korea United Pharm Inc
Le Sun Pharmaceuticals Ltd
Oncoheroes Biosciences Inc
Onconova Therapeutics Inc
PhoreMost Ltd
Takeda Pharmaceutical Co Ltd
Trovagene Inc
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Cyclacel Pharmaceuticals Inc
Korea United Pharm Inc
Le Sun Pharmaceuticals Ltd
Oncoheroes Biosciences Inc
Onconova Therapeutics Inc
PhoreMost Ltd
Takeda Pharmaceutical Co Ltd
Trovagene Inc
